Mucin 5AC Serves as the Nexus for β-Catenin/c-Myc Interplay to Promote Glutamine Dependency During Pancreatic Cancer Chemoresistance
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved..
BACKGROUND & AIMS: A major clinical challenge for patients with pancreatic cancer (PC) is metabolic adaptation. Neoplastic cells harboring molecular perturbations suffice for their increased anabolic demand and nucleotide biosynthesis to acquire chemoresistance. The mucin 5AC expressed de novo in malignant pancreas promotes cancer cell stemness and is significantly associated with poor patient survival. Identification of MUC5AC-associated drivers of chemoresistance through metabolic alterations may facilitate the sculpting of a new combinatorial regimen.
METHODS: The contributions of MUC5AC to glutaminolysis and gemcitabine resistance were examined by The Cancer Genome Atlas data analysis, RNA sequencing, and immunohistochemistry analysis on pancreatic tissues of KrasG12D;Pdx1-Cre (KC) and KrasG12D;Pdx1-Cre;Muc5ac-/- mice. These were followed by metabolite flux assays as well as biochemical and xenograft studies on MUC5AC-depleted human and murine PC cells. Murine and human pancreatic 3-dimensional tumoroids were used to evaluate the efficacy of gemcitabine in combination with β-catenin and glutaminolysis inhibitors.
RESULTS: Transcriptional analysis showed that high MUC5AC-expressing human and autochthonous murine PC tumors exhibit higher resistance to gemcitabine because of enhanced glutamine use and nucleotide biosynthesis. Gemcitabine treatment led to MUC5AC overexpression, resulting in disruption of E-cadherin/β-catenin junctions and the nuclear translocation of β-catenin, which increased c-Myc expression, with a concomitant rise in glutamine uptake and glutamate release. MUC5AC depletion and glutamine deprivation sensitized human PC cells to gemcitabine, which was obviated by glutamine replenishment in MUC5AC-expressing cells. Coadministration of β-catenin and glutaminolysis inhibitors with gemcitabine abrogated the MUC5AC-mediated resistance in murine and human tumoroids.
CONCLUSIONS: The MUC5AC/β-catenin/c-Myc axis increases the uptake and use of glutamine in PC cells, and cotargeting this axis along with gemcitabine may improve therapeutic efficacy in PC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:162 |
|---|---|
| Enthalten in: |
Gastroenterology - 162(2022), 1 vom: 01. Jan., Seite 253-268.e13 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ganguly, Koelina [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.01.2022 Date Revised 04.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1053/j.gastro.2021.09.017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330764985 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330764985 | ||
| 003 | DE-627 | ||
| 005 | 20240404232604.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1053/j.gastro.2021.09.017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1364.xml |
| 035 | |a (DE-627)NLM330764985 | ||
| 035 | |a (NLM)34534538 | ||
| 035 | |a (PII)S0016-5085(21)03496-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ganguly, Koelina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mucin 5AC Serves as the Nexus for β-Catenin/c-Myc Interplay to Promote Glutamine Dependency During Pancreatic Cancer Chemoresistance |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.01.2022 | ||
| 500 | |a Date Revised 04.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND & AIMS: A major clinical challenge for patients with pancreatic cancer (PC) is metabolic adaptation. Neoplastic cells harboring molecular perturbations suffice for their increased anabolic demand and nucleotide biosynthesis to acquire chemoresistance. The mucin 5AC expressed de novo in malignant pancreas promotes cancer cell stemness and is significantly associated with poor patient survival. Identification of MUC5AC-associated drivers of chemoresistance through metabolic alterations may facilitate the sculpting of a new combinatorial regimen | ||
| 520 | |a METHODS: The contributions of MUC5AC to glutaminolysis and gemcitabine resistance were examined by The Cancer Genome Atlas data analysis, RNA sequencing, and immunohistochemistry analysis on pancreatic tissues of KrasG12D;Pdx1-Cre (KC) and KrasG12D;Pdx1-Cre;Muc5ac-/- mice. These were followed by metabolite flux assays as well as biochemical and xenograft studies on MUC5AC-depleted human and murine PC cells. Murine and human pancreatic 3-dimensional tumoroids were used to evaluate the efficacy of gemcitabine in combination with β-catenin and glutaminolysis inhibitors | ||
| 520 | |a RESULTS: Transcriptional analysis showed that high MUC5AC-expressing human and autochthonous murine PC tumors exhibit higher resistance to gemcitabine because of enhanced glutamine use and nucleotide biosynthesis. Gemcitabine treatment led to MUC5AC overexpression, resulting in disruption of E-cadherin/β-catenin junctions and the nuclear translocation of β-catenin, which increased c-Myc expression, with a concomitant rise in glutamine uptake and glutamate release. MUC5AC depletion and glutamine deprivation sensitized human PC cells to gemcitabine, which was obviated by glutamine replenishment in MUC5AC-expressing cells. Coadministration of β-catenin and glutaminolysis inhibitors with gemcitabine abrogated the MUC5AC-mediated resistance in murine and human tumoroids | ||
| 520 | |a CONCLUSIONS: The MUC5AC/β-catenin/c-Myc axis increases the uptake and use of glutamine in PC cells, and cotargeting this axis along with gemcitabine may improve therapeutic efficacy in PC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Video-Audio Media | |
| 650 | 4 | |a Gemcitabine | |
| 650 | 4 | |a Glutamine | |
| 650 | 4 | |a Pancreatic Cancer | |
| 650 | 4 | |a c-Myc | |
| 650 | 4 | |a β-Catenin | |
| 650 | 7 | |a Antimetabolites, Antineoplastic |2 NLM | |
| 650 | 7 | |a CTNNB1 protein, human |2 NLM | |
| 650 | 7 | |a CTNNB1 protein, mouse |2 NLM | |
| 650 | 7 | |a Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a MUC5AC protein, human |2 NLM | |
| 650 | 7 | |a MYC protein, human |2 NLM | |
| 650 | 7 | |a Muc5ac protein, mouse |2 NLM | |
| 650 | 7 | |a Mucin 5AC |2 NLM | |
| 650 | 7 | |a Myc protein, mouse |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-myc |2 NLM | |
| 650 | 7 | |a beta Catenin |2 NLM | |
| 650 | 7 | |a Glutamine |2 NLM | |
| 650 | 7 | |a 0RH81L854J |2 NLM | |
| 650 | 7 | |a Deoxycytidine |2 NLM | |
| 650 | 7 | |a 0W860991D6 |2 NLM | |
| 650 | 7 | |a GLS protein, human |2 NLM | |
| 650 | 7 | |a EC 3.5.1.2 |2 NLM | |
| 650 | 7 | |a GLS1 protein, mouse |2 NLM | |
| 650 | 7 | |a EC 3.5.1.2 |2 NLM | |
| 650 | 7 | |a Glutaminase |2 NLM | |
| 650 | 7 | |a EC 3.5.1.2 |2 NLM | |
| 650 | 7 | |a Gemcitabine |2 NLM | |
| 700 | 1 | |a Bhatia, Rakesh |e verfasserin |4 aut | |
| 700 | 1 | |a Rauth, Sanchita |e verfasserin |4 aut | |
| 700 | 1 | |a Kisling, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Atri, Pranita |e verfasserin |4 aut | |
| 700 | 1 | |a Thompson, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Vengoji, Raghupathy |e verfasserin |4 aut | |
| 700 | 1 | |a Ram Krishn, Shiv |e verfasserin |4 aut | |
| 700 | 1 | |a Shinde, Dhananjay |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Vinai |e verfasserin |4 aut | |
| 700 | 1 | |a Kaur, Sukhwinder |e verfasserin |4 aut | |
| 700 | 1 | |a Mallya, Kavita |e verfasserin |4 aut | |
| 700 | 1 | |a Cox, Jesse L |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Sushil |e verfasserin |4 aut | |
| 700 | 1 | |a Batra, Surinder K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gastroenterology |d 1945 |g 162(2022), 1 vom: 01. Jan., Seite 253-268.e13 |w (DE-627)NLM00001706X |x 1528-0012 |7 nnns |
| 773 | 1 | 8 | |g volume:162 |g year:2022 |g number:1 |g day:01 |g month:01 |g pages:253-268.e13 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1053/j.gastro.2021.09.017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 162 |j 2022 |e 1 |b 01 |c 01 |h 253-268.e13 | ||